FDA Regulatory Consulting for Biotech Startups

Senior-led FDA regulatory consulting for biotech startups developing biologics, cell and gene therapies, and combination products with complex paths to the clinic.

Trusted in High-Risk FDA Integrity Cases

Chosen for nearly two dozen FDA data-integrity audits.

Inspection-Ready Clinical Operations

Clinical discipline shaped by decades of FDA scrutiny.

30+ Years in Complex Devices & Biotech

Guiding high‑stakes medtech and biotech programs from early strategy to market.

A Clear, Defensible FDA Path for Early-Stage Biotech

Biotech startups face critical FDA decisions long before the first patient is enrolled. Many are also caught in the middle, running programs that look more like drug development than device work on budgets that aren’t built for pharma-scale CROs and vendors.

Health Policy Associates (HPA) has provided regulatory and clinical guidance to biologic, cellular, and gene therapy companies for more than two decades, including managing five concurrent Phase 2 studies for a prominent stem cell therapy program. Our biotech consulting gives lean teams senior clinical and regulatory expertise without enterprise overhead.

“HPA’s understanding of FDA compliance is light years above everybody else’s. They work collaboratively with the sites. They can see what’s happening that might be a problem and fix it rather than just documenting it after the fact.”

— Roger Brown

Therapeutic Area Head, Musculoskeletal Repair, Mesoblast

HPA Helps Biotech Startups Answer Five Practical Questions

01Will the FDA regulate our product as a biologic, a device, or a combination product?
02What does the FDA need to see before we can begin clinical trials?
03Where are the real gaps in our preclinical, manufacturing, and clinical plan?
04What should we ask the FDA in our first meeting, and when?
05How do we explain our regulatory path and risks to our board and investors?

We provide you with a concrete regulatory plan: clear documents and working sessions that turn uncertainty into a development path you can defend to your board and investors.

Where Biotech Startups Typically Engage HPA

Most engagements begin at a moment when the next FDA decision will shape the program’s cost, timeline, and credibility with investors.

Your first formal interaction with the FDA sets the tone for the rest of the program. Sponsors who arrive with broad, unfocused questions often leave with feedback that is too general to act on.

We help guide your preparation for a pre-IND meeting, or an INTERACT meeting with the FDA’s Center for Biologics Evaluation and Research (CBER), and then translate the agency’s feedback into clear, prioritized next steps. When a program needs specialized IND expertise, we bring in experienced outside specialists and coordinate the work alongside our own team.

Many biotech products don’t fit neatly into one regulatory category. How the FDA classifies your product determines which center leads the review, what evidence you’ll need, and how long and costly the path to market will be.

We assess how the agency is likely to classify your product and build a defensible rationale before you commit to a direction — including for combination products that sit at the boundary of two regulatory frameworks.

A product with biologic components may even qualify as a device when its primary function is physical, which can significantly reduce development time and cost.

Investors increasingly evaluate the regulatory path as closely as the science, and an unclear pathway or optimistic timeline can raise difficult questions.

We build a regulatory plan that details the pathway, evidence requirements, key FDA milestones, and the risks most likely to affect your schedule and funding. We then summarize it in clear business language your leadership can confidently present to the board and investors.

As preclinical work nears completion, many startups need a partner for their first clinical trial, which is often where budgets come under pressure.

We develop a protocol that is feasible, enrollable, and aligned with FDA expectations. Because we handle regulatory, clinical, and quality work under one roof, your FDA commitments and trial operations stay aligned from the start. We can also support later-stage trials as your product advances.

A clinical hold or critical FDA feedback can stop a program in its tracks — and put the next funding milestone at risk. We help you identify what the FDA actually needs, trace the root causes, and build a response designed to restore momentum.

Our own clinical program has been through a six-day direct FDA inspection with zero observations, so we know what the agency looks for when it takes a close look.

Why Medtech and Biotech Sponsors Choose HPA

Get Actionable Clarity

We translate FDA expectations for biologics and novel therapies into a clear development plan, so your lean team knows what to do now and what can wait.

Defend Your Decisions Under FDA Scrutiny

We help you make classification, preclinical, and clinical decisions that hold up when the FDA, your board, and investors start asking hard questions.

Keep A Stable, Senior Team — And A Predictable Budget

The same senior consultants stay with your program from first FDA interaction into the clinic, with disciplined scoping that keeps costs under control.

What To Expect From HPA’s Regulatory Consulting for Biotech Startups

The scope of a biotech engagement depends on your product type, where you are in development, and what the FDA has already said. Typical engagements include some or all of the following:

FDA Path and Submission Map

A regulatory pathway opinion outlining how the FDA is likely to classify your product, which submissions and meetings lie ahead, and the timing and resource implications for your development plan.

Regulatory Gap Assessment

A review of your current preclinical, manufacturing, and clinical evidence against FDA expectations, identifying what is missing or misaligned.

Regulatory Action Plan

A prioritized roadmap that sequences the required testing, documentation, and FDA interactions, so your team knows what to do, in what order, and why.

Submission Support

Coordination of key regulatory submissions, such as pre-IND briefing packages and IND sections, with experienced outside specialists brought in to lead the drafting where your program needs it.

Executive Summary

Concise materials that explain the recommended path, key risks, and next steps for leadership, boards, and investors.

These deliverables follow the same approach behind our Regulatory Consulting Services, adapted to the realities of an early-stage biotech company.

Extended Support When Needed

Some biotech programs need support beyond regulatory strategy. When the work demands it, we can extend the engagement to include:

when your program moves into clinical studies and you need protocol development, site management, monitoring, and data analysis under one roof.

when your product pairs a biologic or drug with a device and lead-center determination or cross-center coordination must be resolved.

when manufacturing processes, suppliers, or quality systems need to be ready for FDA scrutiny before your program scales.

when your study needs database design, real-time data access, and customized analysis that will hold up in a regulatory submission.

We scope these extensions based on your program’s specific needs and can connect the work directly to our Clinical Trial Strategy & Execution, Combination Product Consulting, Quality Systems / Compliance Consulting, US FDA GMP Auditing, and Data Management and Analysis services.

What to Expect When You Work With HPA

1
Initial Call & Biotech Program Triage
We start with a short call to understand your product, its development stage, your funding milestones, and any prior FDA interactions. You get a candid view of whether HPA is the right fit and what type of engagement makes sense.
2
Light Documentation Review
We review a small set of key documents, such as a product overview, preclinical summary, or recent FDA correspondence, to confirm we can help and to scope the work.
3
Scope, Proposal & Engagement Plan
You receive a clear proposal outlining the engagement scope, deliverables, timeline, and fees, including how the work will adjust as your program moves into clinical development or reaches new funding milestones.
4
Kickoff & Structured Regulatory Review
Once engaged, we hold a kickoff to align on objectives and roles, then review your product characterization, preclinical data, and development plan. Where appropriate, we also review applicable FDA guidance, relevant regulations, and publicly available information to inform the strategy.
5
Pathway Strategy, Gap Assessment & Action Plan
We confirm the likely regulatory pathway, assess your evidence against FDA expectations, and deliver a prioritized action plan with clear milestones your team and investors can follow.
6
FDA Interaction Support & Ongoing Advisory
We support your team through FDA interactions, interpret feedback, and provide executive summaries for leadership and investors so the program stays on track.

When your program is ready to begin clinical studies, we can extend the engagement into Clinical Trial Strategy & Execution, so your regulatory commitments and trial operations stay aligned.

“I think HPA’s level of quality and the level of detail they work at, because of their background with auditing, is at a completely different level than your average monitoring service or large CRO.”

— Roger Brown

Therapeutic Area Head, Musculoskeletal Repair, Mesoblast

Put Senior Regulatory Judgment Behind Your Path to the Clinic

For a biotech startup, the regulatory decisions made before the first clinical trial shape everything that follows, from how the FDA reviews your product to how investors value your company.

HPA works alongside your leadership so you can choose a defensible path, close the gaps that matter, and move into clinical development with a plan your team, board, and investors can stand behind.